"Cytochrome P-450 CYP2C9" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cytochrome P-450 subtype that has specificity for acidic XENOBIOTICS. It oxidizes a broad range of important clinical drugs that fall under the categories of NONSTEROIDAL ANTI-INFLAMMATORY AGENTS; HYPOGLYCEMIC AGENTS; ANTCOAGULANTS; and DIURETICS.
| Descriptor ID |
D065729
|
| MeSH Number(s) |
D08.244.453.491.500.500 D08.811.682.690.708.170.450.500.500 D12.776.422.220.453.491.500.500
|
| Concept/Terms |
Cytochrome P-450 CYP2C9- Cytochrome P-450 CYP2C9
- CYP2C9, Cytochrome P-450
- Cytochrome P 450 CYP2C9
- P-450 CYP2C9, Cytochrome
- Cytochrome P450 PB-1
- Cytochrome P450 PB 1
- P450 PB-1, Cytochrome
- PB-1, Cytochrome P450
- Cytochrome P450 MP-4
- Cytochrome P450 MP 4
- MP-4, Cytochrome P450
- P450 MP-4, Cytochrome
- Cytochrome P450 MP-8
- Cytochrome P450 MP 8
- MP-8, Cytochrome P450
- P450 MP-8, Cytochrome
- CYP2C9
- CYPIIC9
|
Below are MeSH descriptors whose meaning is more general than "Cytochrome P-450 CYP2C9".
Below are MeSH descriptors whose meaning is more specific than "Cytochrome P-450 CYP2C9".
This graph shows the total number of publications written about "Cytochrome P-450 CYP2C9" by people in this website by year, and whether "Cytochrome P-450 CYP2C9" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cytochrome P-450 CYP2C9" by people in Profiles.
-
Raymond M, Critchlow E, Rice SM, Wodoslawsky S, Berger SI, Hegde M, Empey PE, Al-Kouatly HB. Fetal pharmacogenomics: A promising addition to complex neonatal care. Mol Genet Metab. 2022 Sep-Oct; 137(1-2):140-145.
-
Karnes JH, Rettie AE, Somogyi AA, Huddart R, Fohner AE, Formea CM, Ta Michael Lee M, Llerena A, Whirl-Carrillo M, Klein TE, Phillips EJ, Mintzer S, Gaedigk A, Caudle KE, Callaghan JT. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update. Clin Pharmacol Ther. 2021 02; 109(2):302-309.
-
Eriksson N, Wallentin L, Berglund L, Axelsson T, Connolly S, Eikelboom J, Ezekowitz M, Oldgren J, Par? G, Reilly P, Siegbahn A, Syvanen AC, Wadelius C, Yusuf S, Wadelius M. Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy. Pharmacogenomics. 2016 08; 17(13):1425-39.
-
Caudle KE, Rettie AE, Whirl-Carrillo M, Smith LH, Mintzer S, Lee MT, Klein TE, Callaghan JT. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. Clin Pharmacol Ther. 2014 Nov; 96(5):542-8.
-
Ellis DJ, Usman MH, Milner PG, Canafax DM, Ezekowitz MD. The first evaluation of a novel vitamin K antagonist, tecarfarin (ATI-5923), in patients with atrial fibrillation. Circulation. 2009 Sep 22; 120(12):1029-35, 2 p following 1035.